Geron

#6067

Rank

$931.5M

Marketcap

United States

Country

Leadership team

Ms. Olivia Kyusuk Bloom (Exec. VP of Fin., CFO & Treasurer)

Dr. John A. Scarlett M.D. (Chairman, Pres & CEO)

Dr. Andrew J. Grethlein (Exec. VP & COO)

Products/ Services

Biopharma, Biotechnology, Health Diagnostics, Pharmaceutical

Number of Employees

50 - 100

Headquarters

Menlo Park, California, United States

Established

1990

Company Registration

SEC CIK number: 0000886744

Revenue

500K - 2M

Traded as

GERN

Social Media

URL

https://www.geron.com

Overview

Location

Recognition and Award

References

Summary

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

History

Geron Corporation was founded in 1990. In the early years, the company focused on the development of small-molecule pharmaceuticals, and in 2009, Geron transitioned to a full-time focus on the development of therapeutics for oncology and stem cell-based regenerative medicine applications.

Mission

Geron Corporation's mission is to develop therapeutics that have the potential to meaningfully improve and extend the lives of individuals with life-threatening and debilitating diseases.

Vision

Geron Corporation's vision is to become a leader in the discovery and development of life-saving and life-changing drugs that address unmet medical needs.

Key Team

Ms. Melissa A. Kelly Behrs (Exec. VP of Bus. Operations & Chief Alliance Officer)

Ms. Aron Feingold (VP of Investor Relations & Corp. Communications)

Mr. Stephen N. Rosenfield J.D. (Exec. VP, Chief Legal Officer & Corp. Sec.)

Mr. Anil Kapur (Exec. VP of Corp. Strategy & Chief Commercial Officer)

Ms. Shannon Odam (VP of HR)

Mr. Edward E. Koval (Exec. VP & Chief Bus. Officer)

Dr. Faye Feller M.D. (Exec. VP & Chief Medical Officer)

Recognition and Awards

Geron Corporation was recognized as an Outstanding Performer by the consulting firm Avalere Health in 2020 and is a multiple recipient of the R&D 100 Award for excellence in research and development. The company has also received international and national awards for its therapeutic programs targeting cancer and other diseases.